Agilent Technologies Inc vs Akamai Technologies, Inc. — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Akamai Technologies, Inc. trades at $116.89 (market cap $16.91B). The key difference: Agilent Technologies Inc is far larger — about 2.5× Akamai Technologies, Inc.'s market cap, and Agilent Technologies Inc pays a 0.69% dividend while Akamai Technologies, Inc. pays none. Which is the better fit depends on your goals.
| A | AKAM | |
|---|---|---|
Market Cap | $42.00B | $16.91B |
Sector | Health | Technology |
52-Week High | $157.20 | $161.14 |
52-Week Low | $110.24 | $71.97 |
Enterprise Value | $43.55B | $22.89B |
Dividend Yield | 0.69% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Akamai Technologies (AKAM) trades at $110.54, down 6.76% over 24 hours, reflecting recent volatility despite strong Q2 2026 earnings beats. The stock shows bearish technical signals with support at $105 and resistance at $115, while fundamentals reveal revenue growth to $4.21 billion in 2025 but declining net margins to 9.51%. Analyst sentiment is mixed with a consensus price target of $152.60, and news highlights AI-driven cloud demand boosting performance.
Outlook remains cautious due to margin pressures from infrastructure investments, though AI and cybersecurity growth offer upside. Risks include competitive threats and execution challenges. Investors should weigh solid cash flow against high P/E of 40.05, with institutional hold ratings at 49.02% suggesting neutral near-term momentum.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →